Oppenheimer set a $10.00 price target on TherapeuticsMD (NASDAQ:TXMD) in a research report sent to investors on Wednesday morning. The brokerage currently has a buy rating on the stock. Oppenheimer also issued estimates for TherapeuticsMD’s FY2020 earnings at $0.27 EPS and FY2021 earnings at $0.45 EPS.
Other analysts also recently issued reports about the stock. BidaskClub raised shares of TherapeuticsMD from a strong sell rating to a sell rating in a research report on Friday, February 9th. Noble Financial reissued a buy rating on shares of TherapeuticsMD in a research report on Thursday, November 30th. Deutsche Bank set a $9.00 target price on shares of TherapeuticsMD and gave the stock a buy rating in a research report on Wednesday, December 20th. Cantor Fitzgerald reissued a buy rating and issued a $31.00 target price on shares of TherapeuticsMD in a research report on Wednesday, November 29th. Finally, Cowen reissued an outperform rating and issued a $16.00 target price (up from $13.00) on shares of TherapeuticsMD in a research report on Monday, November 6th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of $14.50.
Shares of TherapeuticsMD (NASDAQ:TXMD) opened at $5.37 on Wednesday. TherapeuticsMD has a 1 year low of $3.50 and a 1 year high of $8.30.
TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Tuesday, February 20th. The company reported ($0.10) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.01). The business had revenue of $4.13 million during the quarter, compared to the consensus estimate of $4.66 million. TherapeuticsMD had a negative return on equity of 65.30% and a negative net margin of 458.49%. The business’s revenue was down 8.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.12) earnings per share. equities research analysts anticipate that TherapeuticsMD will post -0.38 earnings per share for the current fiscal year.
In other news, Director Tommy G. Thompson acquired 5,000 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The stock was acquired at an average cost of $6.21 per share, with a total value of $31,050.00. Following the acquisition, the director now owns 3,555 shares in the company, valued at $22,076.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 23.92% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of TXMD. JPMorgan Chase & Co. boosted its holdings in shares of TherapeuticsMD by 40.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 22,027,855 shares of the company’s stock worth $112,783,000 after buying an additional 6,340,346 shares during the period. BlackRock Inc. boosted its holdings in shares of TherapeuticsMD by 29.7% during the 4th quarter. BlackRock Inc. now owns 14,431,862 shares of the company’s stock worth $87,169,000 after buying an additional 3,307,477 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of TherapeuticsMD by 12.0% during the 4th quarter. Bank of New York Mellon Corp now owns 28,973,668 shares of the company’s stock worth $175,001,000 after buying an additional 3,095,804 shares during the period. Ardsley Advisory Partners boosted its holdings in shares of TherapeuticsMD by 4,100.0% during the 4th quarter. Ardsley Advisory Partners now owns 1,050,000 shares of the company’s stock worth $6,342,000 after buying an additional 1,025,000 shares during the period. Finally, Franklin Resources Inc. boosted its holdings in shares of TherapeuticsMD by 5.9% during the 4th quarter. Franklin Resources Inc. now owns 10,992,409 shares of the company’s stock worth $66,394,000 after buying an additional 612,965 shares during the period. 71.40% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “TherapeuticsMD (TXMD) PT Set at $10.00 by Oppenheimer” was first posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://transcriptdaily.com/2018/02/25/therapeuticsmd-txmd-pt-set-at-10-00-by-oppenheimer.html.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.